New Delhi, May 6 -- Orbicular Pharmaceutical Technologies Pvt. Ltd., a specialty pharmaceutical company focused on complex generics and peptide-based therapeutics, today announced that a generic version of Ozempic (semaglutide injection), developed in partnership with Apotex, has received a Notice of Compliance (NOC) from Health Canada. The product will be marketed and commercialized in Canada by Apotex Inc., the applicant of record and Canada's largest pharmaceutical company.

The market authorization covers two presentations - 2 mg / 3 mL (0.68 mg/mL) and 4 mg / 3 mL (1.34 mg/mL) - matching the concentration and fill-volume profile of the reference product, which patients and prescribers in Canada are already familiar with. This approva...